Changes in lipid and lipoprotein profile in postmenopausal women receiving low-dose combinations of 17β-estradiol and norethisterone acetate

Menopause

Volumn 9, Issue 5, 2002, Pages 335-342

  Samsioe, Göran ^a   Li, Cairu ^a   Borgfeldt, Christer ^a   Wilawan, Kittisak ^b   Åberg, Anders ^a   Larsen, Sören ^c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b PRAMONGKUTKLAO HOSPITAL   (Thailand)

^c NOVO NORDISK A S   (Denmark)

Author keywords

Estradiol; Hormone replacement therapy; Lipid; Lipoprotein; Norethisterone acetate

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; CHOLESTEROL; ESTRADIOL PLUS NORETHISTERONE ACETATE; LIPID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; DRUG DERIVATIVE; ESTRADIOL; NORETHISTERONE; NORETHISTERONE ACETATE;

ADULT; AGED; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; HYPOLIPEMIA; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; TIME SERIES ANALYSIS; BLOOD; DRUG COMBINATION; ESTROGEN THERAPY; MIDDLE AGED; POSTMENOPAUSE; TREATMENT OUTCOME;

AGED; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LIPIDS; LIPOPROTEINS; MIDDLE AGED; NORETHINDRONE; POSTMENOPAUSE; TREATMENT OUTCOME;

EID: 0036728322     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042192-200209000-00006     Document Type: Article

References (39)

1. Fukami K, Koike K, Hirota K, et al. Perimenopausal changes in serum lipids and lipoproteins: a 7-year longitudinal study. Maturitas 1995;22:193-197.
2. de Aloysio D, Gambacciani M, Meschia M, et al. The effect of menopause on blood lipid and lipoprotein levels: the Icarus Study Group. Atherosclerosis 1999;147:147-153.
3. Jensen J, Nilas L, Christiansen C. Influence of menopause on serum lipids and lipoproteins. Maruritas 1990;12:321-331.
4. Barrett-Connor E, Slone S, Greendale G, et al. The postmenopausal estrogen/progestin interventions study: primary outcomes in adherent women. Maturitas 1997;27:261-264.
5. Godsland IF. The influence of female sex steroids on glucose metabolism and insulin action. J Int Med 1996;240(Suppl 738):iii-60.
6. Lindoff C, Petersson F, Lecander I, et al. Transdermal estrogen replacement therapy: beneficial effects on haemostatic risk factors for cardiovascular disease. Maturitas 1996;24:43-50.
7. Rosano GMC, Leonardo F, Chierchia SL. Non-lipid mechanisms of estrogen effects on the coronary vasculature. In: Lippert TH, Mueck AO, Ginsburg J, eds. Sex steroid and the cardiovascular system. London: The Parthenon Publishing Group, 1998:87-95.
8. Lipid Research Clinics' Program Coronary Primary Trial. The Lipid Research Clinics' Program Coronary Primary Trial Results: II - the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:367-374.
9. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991;265:1861-1867.
10. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996;348:977-980.
11. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933-941.
12. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613.
13. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-529.
14. Collins A, Landgren BM. Psychosocial factors associated with the use of hormonal replacement therapy in a longitudinal follow-up of Swedish women. Maturitas 1997;28:1-9.
15. Li C, Samsioe G, Lidfelt J, Nerbrand C, Agardh CD. Important factors for use of hormone replacement therapy: a population-based study of Swedish women. The Women's Health in Lund Area (WHILA) Study. Menopause 2000;7:273-281.
16. Christensen MS, Hagen C, Christiansen C, Transbol I. Dose response evaluation of cyclic estrogen/gestagen in postmenopausal women: placebo-controlled trial of its gynecologic and metabolic actions. Obstet Gynecol 1982;144:873-979.
17. Archer DF, Dorin MH, Heine W, Nanavati N, Arce JC. Uterine bleeding in postmenopausal women on continuous therapy with estradiol and norethindrone acetate. Obstet Gynecol 1999;94:323- 329.
18. Bärug U, Winge T, Nordland G, et al. Do combinations of 1 mg estradiol and low doses of NETA effectively control menopausal symptoms? Climacteric 1998;1:219-228.
19. Delmas PD, Confavreux E, Garnero P, et al. A combination of low doses of 17β-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women. Osteoporos Int 2000;11:177-187.
20. Davidson MH, Maki KC, Marx P, et al. Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women. Arch Intern Med 2000;160:3315-3325.
21. Stadberg E, Mattsson LÅ, Uvebrant M. Low doses of 17β-estradiol and norethisterone acetate as continuous combined replacement therapy in postmenopausal women: lipid metabolic effects. Menopause 1996;3:90-96
22. Farish E, Fletcher CD, Hart DM, et al. A long-term study of the effects of norethisterone on lipoprotein metabolism in menopausal women. Clin Chim Acta 1983; 132:193-198.
23. Farish E, Rolton HA, Barnes JF, Hart DM. Lipoprotein (a) concentrations in postmenopausal women taking norethisterone. BMJ 1991;303:694.
24. Jensen J, Riis BJ, Strom V, Christiansen C. Long-term and withdrawal effects of two different oestrogen-progestogen combinations on lipid and lipoprotein profiles in post-menopausal women. Maturitas 1989;11:117-128.
25. Alexandersen P, Haarbo J, Sandholdt I, Shalmi M, Lawaetz H, Christiansen C. Norethindrone acetate enhances the antiatherogenic effect of 17β-estradiol: a secondary prevention study of aortic atherosclerosis in ovariectomized cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol 1998;18:902-907.
26. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results: I - reduction in incidence of coronary heart disease. JAMA 1984;251:351-364.
27. Christiansen C, Riis BJ. Five years with continuous combined oestrogen/progestogen therapy: effects on calcium metabolism, lipoproteins, and bleeding pattern. Br J Obstet Gynaecol 1990;97:1087-1092.
28. Ylikorkala O, Lim P, Caubel P. Effects on serum lipid profiles of continuous 17β-estradiol, intermittent norgestimate regimens versus continuous combined 17β-estradiol/norethisterone acetate hormone replacement therapy. Clin Ther 2000;22:622-636.
29. Notelovitz M, Gudat JC, Ware MD, Dougherty M. Lipids and lipoproteins in women after oophorectomy and the response to oestrogen therapy. Br J Obstet Gynaecol 1983;90:171-177.
30. Tikkanen MJ, Nikkila EA, Kuusi T, et al. High density lipoprotein-2 and hepatic lipase: reciprocal changes produced by estrogen and norgestrel. J Clin Endocrinol Metab 1982;54:1113-1117.
31. von Eckardstein A, Assmann G. Prevention of coronary heart disease by raising high density lipoprotein cholesterol? Curr Opin Lipidol 2000;11:627-637.
32. Matthews KA, Meilahn E, Kuller L, et al. Menopause and risk factors for coronary heart disease. N Engl J Med 1989;321:641-646.
33. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998;81:7B-12B.
34. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions PEPI Trial. JAMA 1995;273:199-208.
35. Samsioe G. Lipid profiles in oestrogen users. In: Sitruk-Ware R, Utian W, eds. The menopause and hormonal replacement therapy. New York: Marcel Dekker, 1991:181-200.
36. Murai A, Miyaham T, Fijimote N. Lp (a) lipoprotein risk factors for coronary heart disease and cerebral infarction. Atherosclerosis 1986;59:199-203.
37. Scanu AM, Lawwn RM, Berg K. Lipoprotein (a) and atherosclerosis. Ann Intern Med 1991;115:209-218.
38. Jenner JL, Ordovas JM, Lamon-Fava S, et al. Effects of age, sex, and menopausal status on plasma lipoprotein (a) levels. The Framingham Offspring Study. Circulation 1993;87:1135-1141.
39. Espeland MA, Marcovina SM, Miller V, et al. Effect of postmenopausal hormone therapy on lipoprotein (a) concentration. Circulation 1998;97:979-986.